Clinical Trial Update: Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA [Phase 4]

View source ↗

Summary

Phase 4 trial comparing continuing lamivudine versus switching to entecavir in patients with chronic hepatitis B who achieved undetectable HBV DNA; study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Entecavir (Baraclude) (Entecavir)
• Lamivudine (Epivir) (lamivudine)

Snippet

Sponsor: Pusan National University Hospital | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED